High-dose therapy and autologous stem cell transplantation for multiple myeloma poorly responsive to initial therapy-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

High-dose therapy and autologous stem cell transplantation for multiple myeloma poorly responsive to initial therapy

Published:2004-05-10 Issue:2 Volume:34 Page:161-167
ISSN:0268-3369
Container-title:Bone Marrow Transplantation
language:en
Short-container-title:Bone Marrow Transplant

Author:

Kumar S,Lacy M Q,Dispenzieri A,Rajkumar S V,Fonseca R,Geyer S,Allmer C,Witzig T E,Lust J A,Greipp P R,Kyle R A,Litzow M R,Gertz M A

Publisher

Springer Science and Business Media LLC

Subject

Transplantation,Hematology

Link

http://www.nature.com/articles/1704545.pdf

Reference40 articles.

1. Bataille R, Harousseau JL . Multiple myeloma. New Engl J Med 1997; 336: 1657–1664.

2. Jemal A, Murray T, Samuels A et al. Cancer statistics, 2003. CA Cancer J Clin 2003; 53: 5–26.

3. Kyle RA . Long-term survival in multiple myeloma. New Engl J Med 1983; 308: 314–316.

4. Alexanian R, Bonnet J, Gehan E et al. Combination chemotherapy for multiple myeloma. Cancer 1972; 30: 382–389.

5. Kyle R, Gertz M, Witzig T et al. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc 2003; 78: 21–33.

Cited by 82 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Should I stay or should I go (to transplant)? Managing insufficient responses to induction in multiple myeloma;Blood Cancer Journal;2023-05-30

2. ASTCT Clinical Practice Recommendations for Transplantation and Cellular Therapies in Multiple Myeloma;Transplantation and Cellular Therapy;2022-06

3. Response-adapted intensification with cyclophosphamide, bortezomib, and dexamethasone versus no intensification in patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial;The Lancet Haematology;2019-12

4. Phase I study of samalizumab in chronic lymphocytic leukemia and multiple myeloma: blockade of the immune checkpoint CD200;Journal for ImmunoTherapy of Cancer;2019-08-23

5. Salvage therapy versus upfront autologous stem cell transplantation in multiple myeloma patients with progressive disease after first-line induction therapy;Leukemia & Lymphoma;2019-08-19

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3